title: Telmisartan is a potent target for prevention and treatment in human prostate cancer.
abstract: Angiotensin II receptor blockers (ARBs) are widely used as hypertensive therapeutic agent. Recent studies have reported that ARBs have the potential to inhibit the growth of prostate cancer (PC) cells. Moreover, it was recently reported that Telmisartan (a kind of ARB) has peroxisome proliferator-activated receptor (PPAR)-gamma activation. We previously reported that PPAR-gamma ligand induces growth arrest of PC cells through apoptosis. In this study, we evaluated the effects of the Telmisartan and other ARBs on cell proliferation in several PC cell lines. We used normal prostate stromal cell (NPC), human hormone-refractory PC (PC3), androgen-independent PC (DU-145) and androgen-dependent PC (LNCaP) cell lines. Effects of Telmisartan and other ARBs (Candesartan, Valsartan, Irbesartan and Losartan) on PC cell growth were examined by MTT assay. Flow cytometry and Hoechst staining were used to determine whether or not ARBs induce apoptosis. Telmisartan caused marked inhibition of PC cells in concentration-dependent and time-dependent manner. PC cells with treatment of 100 microM Telmisartan induced early apoptosis and DNA fragmentation. However, NPC with treatment of 100 microM Telmisartan did not induce apoptosis or DNA fragmentation. Furthermore, other ARBs had no effect on cell proliferation in the PC cells and NPC. Telmisartan may mediate potent antiproliferative effects against PC cells through PPAR-gamma. Thus, Telmisartan is a potent target for prevention and treatment in PC.
authors.affiliation: Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Funao
authors.forename: Masahide
authors.initials: M
authors.lastname: Matsuyama
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kawahito
authors.forename: Hajime
authors.initials: H
authors.lastname: Sano
authors.forename: Jamel
authors.initials: J
authors.lastname: Chargui
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Touraine
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakatani
authors.forename: Rikio
authors.initials: R
authors.lastname: Yoshimura
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001562:Benzimidazoles / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects*; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D047495:PPAR gamma / Q000819:agonists; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000077333:Telmisartan; D014407:Tumor Cells, Cultured
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D047495:PPAR gamma; D000077333:Telmisartan